Description: Vivek Ramaswamy got a pretty special present for his 32nd birthday in August: $1.1 billion in funding from SoftBank and other investors for the audacious biopharmaceutical firm he founded and leads, Roivant Sciences.

Source: Fortune.com

Date: Sep 21, 2017

Link: http://fortune.com/2017/09/21/roivant-sciences-ceos-profile/?iid=leftrail

Questions for discussion:

• What is so unique about this financial structuring?
• Why does it appeal to lenders?
• How does it impact risk?